CN107383203A - A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof - Google Patents
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof Download PDFInfo
- Publication number
- CN107383203A CN107383203A CN201710676329.3A CN201710676329A CN107383203A CN 107383203 A CN107383203 A CN 107383203A CN 201710676329 A CN201710676329 A CN 201710676329A CN 107383203 A CN107383203 A CN 107383203A
- Authority
- CN
- China
- Prior art keywords
- chicken
- ifn
- interferon
- fusion protein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 133
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 75
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 64
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 53
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 53
- 101000599932 Gallus gallus Interferon gamma Proteins 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 102000014150 Interferons Human genes 0.000 claims abstract description 33
- 108010050904 Interferons Proteins 0.000 claims abstract description 33
- 229940079322 interferon Drugs 0.000 claims abstract description 32
- 230000006798 recombination Effects 0.000 claims abstract description 30
- 238000005215 recombination Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 231100000331 toxic Toxicity 0.000 claims abstract description 6
- 230000002588 toxic effect Effects 0.000 claims abstract description 6
- 208000035240 Disease Resistance Diseases 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 230000014509 gene expression Effects 0.000 claims description 36
- 241000894006 Bacteria Species 0.000 claims description 27
- 241000588724 Escherichia coli Species 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 20
- 108010074328 Interferon-gamma Proteins 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 15
- 238000010353 genetic engineering Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000005571 anion exchange chromatography Methods 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims 2
- 101001043815 Ovis aries Interleukin-2 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108700027921 interferon tau Proteins 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 48
- 108010002350 Interleukin-2 Proteins 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 35
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 31
- 108020004705 Codon Proteins 0.000 description 29
- 102000000588 Interleukin-2 Human genes 0.000 description 19
- 230000004087 circulation Effects 0.000 description 17
- 230000009182 swimming Effects 0.000 description 16
- 230000029087 digestion Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 238000012408 PCR amplification Methods 0.000 description 12
- 239000012148 binding buffer Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 102000006382 Ribonucleases Human genes 0.000 description 11
- 108010083644 Ribonucleases Proteins 0.000 description 11
- 238000004925 denaturation Methods 0.000 description 11
- 230000036425 denaturation Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 10
- 238000005457 optimization Methods 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 238000000137 annealing Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- -1 PH6.5) in after Chemical compound 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 2
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 101150034785 gamma gene Proteins 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GORKKVHIBWAQHM-GCJQMDKQSA-N Ala-Asn-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GORKKVHIBWAQHM-GCJQMDKQSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- HFBFSOAKPUZCCO-ZLUOBGJFSA-N Ala-Cys-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HFBFSOAKPUZCCO-ZLUOBGJFSA-N 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
- CPSHGRGUPZBMOK-CIUDSAMLSA-N Arg-Asn-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CPSHGRGUPZBMOK-CIUDSAMLSA-N 0.000 description 1
- NAARDJBSSPUGCF-FXQIFTODSA-N Arg-Cys-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N NAARDJBSSPUGCF-FXQIFTODSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- ZZZWQALDSQQBEW-STQMWFEESA-N Arg-Gly-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZZZWQALDSQQBEW-STQMWFEESA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 1
- ACKNRKFVYUVWAC-ZPFDUUQYSA-N Asn-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ACKNRKFVYUVWAC-ZPFDUUQYSA-N 0.000 description 1
- JXMREEPBRANWBY-VEVYYDQMSA-N Asn-Thr-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JXMREEPBRANWBY-VEVYYDQMSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 1
- LDLZOAJRXXBVGF-GMOBBJLQSA-N Asp-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N LDLZOAJRXXBVGF-GMOBBJLQSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- SARSTIZOZFBDOM-FXQIFTODSA-N Asp-Met-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SARSTIZOZFBDOM-FXQIFTODSA-N 0.000 description 1
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 1
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 1
- KBJVTFWQWXCYCQ-IUKAMOBKSA-N Asp-Thr-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KBJVTFWQWXCYCQ-IUKAMOBKSA-N 0.000 description 1
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- YUZPQIQWXLRFBW-ACZMJKKPSA-N Cys-Glu-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O YUZPQIQWXLRFBW-ACZMJKKPSA-N 0.000 description 1
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 1
- VFGADOJXRLWTBU-JBDRJPRFSA-N Cys-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N VFGADOJXRLWTBU-JBDRJPRFSA-N 0.000 description 1
- BLGNLNRBABWDST-CIUDSAMLSA-N Cys-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N BLGNLNRBABWDST-CIUDSAMLSA-N 0.000 description 1
- DIHCYBRLTVEPBW-SRVKXCTJSA-N Cys-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CS)N DIHCYBRLTVEPBW-SRVKXCTJSA-N 0.000 description 1
- YXPNKXFOBHRUBL-BJDJZHNGSA-N Cys-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N YXPNKXFOBHRUBL-BJDJZHNGSA-N 0.000 description 1
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- QYTKAVBFRUGYAU-ACZMJKKPSA-N Gln-Asp-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QYTKAVBFRUGYAU-ACZMJKKPSA-N 0.000 description 1
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 1
- DDNIZQDYXDENIT-FXQIFTODSA-N Gln-Glu-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N DDNIZQDYXDENIT-FXQIFTODSA-N 0.000 description 1
- SBHVGKBYOQKAEA-SDDRHHMPSA-N Gln-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SBHVGKBYOQKAEA-SDDRHHMPSA-N 0.000 description 1
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 1
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 1
- SSFWXSNOKDZNHY-QXEWZRGKSA-N Gly-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN SSFWXSNOKDZNHY-QXEWZRGKSA-N 0.000 description 1
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- YABRDIBSPZONIY-BQBZGAKWSA-N Gly-Ser-Met Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O YABRDIBSPZONIY-BQBZGAKWSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MWWOPNQSBXEUHO-ULQDDVLXSA-N His-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 MWWOPNQSBXEUHO-ULQDDVLXSA-N 0.000 description 1
- ZJSMFRTVYSLKQU-DJFWLOJKSA-N His-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ZJSMFRTVYSLKQU-DJFWLOJKSA-N 0.000 description 1
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 1
- SKYULSWNBYAQMG-IHRRRGAJSA-N His-Leu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SKYULSWNBYAQMG-IHRRRGAJSA-N 0.000 description 1
- HYWZHNUGAYVEEW-KKUMJFAQSA-N His-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HYWZHNUGAYVEEW-KKUMJFAQSA-N 0.000 description 1
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
- 101001001496 Homo sapiens Interferon gamma receptor 2 Proteins 0.000 description 1
- ZXIGYKICRDFISM-DJFWLOJKSA-N Ile-His-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ZXIGYKICRDFISM-DJFWLOJKSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- MSASLZGZQAXVFP-PEDHHIEDSA-N Ile-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N MSASLZGZQAXVFP-PEDHHIEDSA-N 0.000 description 1
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 1
- JZBVBOKASHNXAD-NAKRPEOUSA-N Ile-Val-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N JZBVBOKASHNXAD-NAKRPEOUSA-N 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 101710174028 Interferon gamma receptor 1 Proteins 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
- IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 description 1
- VIWUBXKCYJGNCL-SRVKXCTJSA-N Leu-Asn-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 VIWUBXKCYJGNCL-SRVKXCTJSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- DXYBNWJZJVSZAE-GUBZILKMSA-N Leu-Gln-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N DXYBNWJZJVSZAE-GUBZILKMSA-N 0.000 description 1
- BOFAFKVZQUMTID-AVGNSLFASA-N Leu-Gln-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N BOFAFKVZQUMTID-AVGNSLFASA-N 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- HNDWYLYAYNBWMP-AJNGGQMLSA-N Leu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N HNDWYLYAYNBWMP-AJNGGQMLSA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- QONKWXNJRRNTBV-AVGNSLFASA-N Leu-Pro-Met Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)N QONKWXNJRRNTBV-AVGNSLFASA-N 0.000 description 1
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- WOEDRPCHKPSFDT-MXAVVETBSA-N Lys-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N WOEDRPCHKPSFDT-MXAVVETBSA-N 0.000 description 1
- YWJQHDDBFAXNIR-MXAVVETBSA-N Lys-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N YWJQHDDBFAXNIR-MXAVVETBSA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- ATNKHRAIZCMCCN-BZSNNMDCSA-N Lys-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N ATNKHRAIZCMCCN-BZSNNMDCSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- YUTZYVTZDVZBJJ-IHPCNDPISA-N Lys-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 YUTZYVTZDVZBJJ-IHPCNDPISA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 1
- KKXGLCPUAWODHF-GUBZILKMSA-N Met-Met-Cys Chemical compound N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(O)=O KKXGLCPUAWODHF-GUBZILKMSA-N 0.000 description 1
- ZDJICAUBMUKVEJ-CIUDSAMLSA-N Met-Ser-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O ZDJICAUBMUKVEJ-CIUDSAMLSA-N 0.000 description 1
- QYIGOFGUOVTAHK-ZJDVBMNYSA-N Met-Thr-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QYIGOFGUOVTAHK-ZJDVBMNYSA-N 0.000 description 1
- FZDOBWIKRQORAC-ULQDDVLXSA-N Met-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N FZDOBWIKRQORAC-ULQDDVLXSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 1
- FCCBQBZXIAZNIG-LSJOCFKGSA-N Pro-Ala-His Chemical compound C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O FCCBQBZXIAZNIG-LSJOCFKGSA-N 0.000 description 1
- OCSACVPBMIYNJE-GUBZILKMSA-N Pro-Arg-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O OCSACVPBMIYNJE-GUBZILKMSA-N 0.000 description 1
- PZSCUPVOJGKHEP-CIUDSAMLSA-N Pro-Gln-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PZSCUPVOJGKHEP-CIUDSAMLSA-N 0.000 description 1
- CMOIIANLNNYUTP-SRVKXCTJSA-N Pro-Gln-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O CMOIIANLNNYUTP-SRVKXCTJSA-N 0.000 description 1
- BODDREDDDRZUCF-QTKMDUPCSA-N Pro-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]2CCCN2)O BODDREDDDRZUCF-QTKMDUPCSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- XERQKTRGJIKTRB-CIUDSAMLSA-N Ser-His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CN=CN1 XERQKTRGJIKTRB-CIUDSAMLSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- HEUVHBXOVZONPU-BJDJZHNGSA-N Ser-Leu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HEUVHBXOVZONPU-BJDJZHNGSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- VOGXLRKCWFLJBY-HSHDSVGOSA-N Thr-Arg-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VOGXLRKCWFLJBY-HSHDSVGOSA-N 0.000 description 1
- JBHMLZSKIXMVFS-XVSYOHENSA-N Thr-Asn-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JBHMLZSKIXMVFS-XVSYOHENSA-N 0.000 description 1
- UTCFSBBXPWKLTG-XKBZYTNZSA-N Thr-Cys-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O UTCFSBBXPWKLTG-XKBZYTNZSA-N 0.000 description 1
- GUZGCDIZVGODML-NKIYYHGXSA-N Thr-Gln-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O GUZGCDIZVGODML-NKIYYHGXSA-N 0.000 description 1
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 1
- AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- UJQVSMNQMQHVRY-KZVJFYERSA-N Thr-Met-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UJQVSMNQMQHVRY-KZVJFYERSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 description 1
- DXDMNBJJEXYMLA-UBHSHLNASA-N Trp-Asn-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 DXDMNBJJEXYMLA-UBHSHLNASA-N 0.000 description 1
- DTPWXZXGFAHEKL-NWLDYVSISA-N Trp-Thr-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DTPWXZXGFAHEKL-NWLDYVSISA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- AOIZTZRWMSPPAY-KAOXEZKKSA-N Tyr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O AOIZTZRWMSPPAY-KAOXEZKKSA-N 0.000 description 1
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 1
- SMKXLHVZIFKQRB-GUBZILKMSA-N Val-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N SMKXLHVZIFKQRB-GUBZILKMSA-N 0.000 description 1
- WKWJJQZZZBBWKV-JYJNAYRXSA-N Val-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WKWJJQZZZBBWKV-JYJNAYRXSA-N 0.000 description 1
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010037389 glutamyl-cysteinyl-lysine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 108010028621 stem cell inhibitory factor Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof; the fusion protein is connected by recombinant chIL-2, chicken interferon gamma with chicken interferon α and formed through flexible linker, through being freeze-dried to obtain recombination chicken long-acting interferon after fusion protein and freeze drying protectant mixture.The recombination chicken long-acting interferon is remarkably improved the half-life period of chicken interferon, and the half-life period of more common chicken interferon improves more than 18 times, and with broad-spectrum disease resistance toxic action and can improve the immune response of chicken itself.
Description
Technical field
The invention belongs to technical field of biological genetic engineering, and in particular to by recombinant chIL-2, chicken interferon gamma and chicken
Fusion protein of interferon-' alpha ' composition and preparation method thereof.
Background technology
In recent years, as the scale of aquaculture and livestock and poultry and products thereof circulation industry rapidly develop, China's domestic fowl farming takes
Tremendous development is obtained, forms the huge industry that annual value of production exceedes hundred billion yuan.Yet with the animal epidemic prevention system that China is weak, poultry diease
It is still the serious problems that China's poultry production faces, this has become an important factor for restricting the development of China's poultry cultivation industry.
Poultry diease is more, loss is big, and the death rate is higher than 15%, and death and culling rate is every up to 20%~25% (developed country is less than 5%), China's poultry husbandry
Chicken The dead quantity year caused by infectious disease is about 300,000,000, about 3,000,000,000 yuan of the economic loss directly contributed, caused by between
Connect about 10,000,000,000 yuan of loss.
Prevention and treatment for chicken viral diseases at present are mainly using vaccine immunity and drug therapy, due to epidemic disease
The immune serotype of seedling is single, and virus serotype is numerous and virus stain speed of mutation is fast, is lost so as to frequently result in vaccine immunity
Lose.Although some antibiotic and the antiviral drugs of chemical synthesis have some effects to a small number of viruses, because medicament residue passes through
Food chain negatively affects to mankind's health care belt, and China prohibited some antibiotic and antiseptic in aquaculture since 16 years
In application.Therefore, be actively developed production have no toxic side effect, drug residue free and the interferon formulation for not producing drug resistance, it is right
The predicament of chicken viral diseases prevention and treatment at present has important clinical meaning.
IFN is that the infection induced body of a viroid is produced with broad-spectrum antiviral, antitumor and with immunoregulation effect
Protein, nineteen fifty-seven, Issacs and Lindeman had found first, and it is a kind of multi-functional cell factor, with cell receptor knot
After conjunction, it can induce body and produce more species-specific proteins and enzyme, mainly by suppressing viral gene transcription and degraded virus
RNA is come the activity that suppresses the growth and breeding of virus and play antitumor grade.Now, it is known that α types IFN in vivo can be selectively
The infection cells such as virus are acted on, by suppressing the biosynthesis of the virus protein in infected cell, play wide spectrum and efficiently
Antivirus action.It is but faint without acting on or acting on to normal host cell.IFN-α main physiological activity is with suppression virus
Duplication, anti parasitic, the killing activity for suppressing various kinds of cell propagation, stimulating immunocyte.
γ types IFN is the T cell and the generation of NK cells by activating, and has relatively strong antiviral and immunoloregulation function.Largely
Research shows that interferon gamma also plays the adjustment effect of key in addition to broad-spectrum antiviral function, to immune system, so
IFN-γ is also known as immunological regulation interferon.Although various types of interferon can mediated cell to virus infection it is anti-
Should, but the immunoregulatory activity of interferon gamma is coordinating immune response and is determining to play more in the long-term antiviral state of body
Important effect, therefore interferon gamma has particularly important clinical value.
Cell factor IL-2 is interleukin 2, also known as SCIF.Mainly produced by the T lymphocytes activated
The cell factor with extensive bioactivity, can both promote lymphopoiesis, strengthen immunologic function, and can restricted T is thin
Born of the same parents react and strengthen the immune tolerance of body, therefore available for treatment tumour, infectious diseases and autoimmune disease.In animal doctor
In, because IL-2 can improve the immune response of vaccine and reduce the generation of disease, also there is wide application prospect.IL-2 is because of energy
Strengthen the immune level of body, improve the resistance against diseases of body, thus exempt from for bacillary, viral and parasitic diseases
Epidemic disease is treated.In addition, IL-2 can also influence the metabolism of medicine, make the metabolism time lengthening of medicine, action time increase, so as to improve
Curative effect of medication.
The limitation of natural interferon and the current generally existing half-life short of artificial recombination interferon, half-life period are generally 2-4
Individual hour.Half-life short brings great inconvenience, the increase for the treatment of number of times, corresponding time cost and financial cost to treatment
Increase therewith, and the tenability limit of body is also possible to be broken the generation for causing adverse reaction.The main reason for half-life short
There are two:The too small tachytrophism in vivo of molecular weight of interferon, interferon especially recombinant interferon affinity is poor to be exempted from
Epidemic disease system is removed.
And common long-acting interferon is using polyethylene glycol fused interferon as representative on the market, only in the aspect of molecular weight
Part solves the problems, such as that interferon molecule amount is small and causes half-life short, while polyethylene glycol fused interferon cost is very
Height, it is unfavorable for clinically applying.
The content of the invention
In order to solve the above technical problems, disturbed the invention provides one kind by recombinant chIL-2, chicken interferon gamma and chicken
Fusion protein of plain α composition and preparation method thereof, and thus fusion protein with after freeze drying protectant mixture, freeze-dried system
Standby to obtain a kind of recombination chicken long-acting interferon, the recombination chicken long-acting interferon is remarkably improved the half-life period of chicken interferon, compared with
The half-life period of common chicken interferon improves more than 18 times, and has broad-spectrum disease resistance toxic action and can improve the immune of chicken itself and answer
Answer.
The technical scheme that the present invention takes is:
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, the fusion protein
Amino acid sequence table as shown in the > of 400 < of SEQUENCE LISTING 1.
Present invention also offers the gene for encoding above-mentioned fusion protein, the nucleotides sequence list such as SEQUENCE of the gene
Shown in the > of 400 < of LISTING 2, genome 1 is designated as;Or as shown in the > of 400 < of SEQUENCE LISTING 3, it is designated as genome 2.
Fusion protein described in 2 equal codified of the genome 1 and the genome.Genome 2 is the nucleosides to genome 1
Acid sequence optimize after result, be considered as the gene in the expression system during usual codon adaptation indexI CAI=1.0
In be optimal high efficient expression state, CAI values are lower to show that expression is lower in host.Most preferable point of G/C content in gene
Cloth scope is 30~70%, and the scope is exceeded in any region can influence translation and transcriptional efficiency.Sent out using software detection
Existing recombinant chIL-2, chicken IFN-γ, the codon of chicken IFN-α original gene codon adaptation indexI in Escherichia coli
(CAI) be respectively 0.27,0.25,0.31, GC percentages be 36.1%, 42.9%, 61.7%;And by chicken interleukin-2
2nd, obtained after chicken IFN-γ, chicken IFN-α gene optimization each gene in Escherichia coli codon adaptation indexI (CAI) be 1.0,
1.0th, 1.0, GC percentages 46.2%, 47.6%, 58.5%.The utilization rate of low codon is significantly reduced by gene optimization,
Influence of the rare codon to protein expression is avoided, the G/C content of gene is improved, improves transcription and translation efficiency.
Present invention also offers the expression vector containing genome 1 or genome 2.
Further, the expression vector is the pET-32a coli expression carriers containing genome 1 or genome 2.
Present invention also offers the genetic engineering bacterium containing genome 1 or genome 2.
Further, the genetic engineering bacterium is pET-32a/rIL2-IFN γ-IFN α.
Host cell containing genome 1 or genome 2 falls within protection scope of the present invention, further, the place
Chief cell is e. coli host cell, and further, the e. coli host cell is BL21 (DE3) competent cell
Or BL21 (DE3) competent cell with pGro7 plasmids.
Present invention also offers a kind of recombination chicken long-acting interferon, the recombination chicken long-acting interferon is by described fusion egg
In vain with after freeze drying protectant mixture, it is freeze-dried to form.
The freeze drying protectant is glycerine, mannitol and sucrose, is buffer solution with 10mmol/L PBS, the final concentration of three
For glycerine 100mL/L, mannitol 0.12g/mL and sucrose 0.025g/mL.
The invention also discloses the preparation method of the fusion protein, the preparation method comprises the following steps:It will contain
The expression vector of genome 1 or genome 2 is imported into e. coli host cell, obtains genetic engineering bacterium, genetic engineering bacterium
The crude product of the fusion protein is obtained after IPTG induced expressions, fusion protein is can obtain after purified.
The expression vector is the pET-32a coli expression carriers containing genome 1 or genome 2;
The genetic engineering bacterium is pET-32a/rIL2-IFN γ-IFN α, and its preparation method is:
(1) primer is designed, is obtained by reverse transcription or the chicken interleukin-2 of the flexible linker sequences of artificial synthesized band
2nd, chicken interferon gamma, chicken interferon α target gene;By flexible linker by recombinant chIL-2, chicken interferon gamma, chicken
The target gene of interferon-' alpha ' connects, the nucleotides sequence list such as SEQUENCE LISTING of the target gene after connection
Shown in the > of 400 < 2 or as shown in the > of 400 < of SEQUENCE LISTING 3;
(2) target gene after connection is connected on pET-32a plasmids and obtains expression vector;
(3) expression vector is imported into e. coli host cell, you can obtain genetic engineering bacterium pET-32a/rIL2-
IFNγ-IFNα。
The e. coli host cell is BL21 (DE3) competent cells or BL21 (DE3) senses with pGro7 plasmids
By state cell.
The method of the purifying is:The crude product of fusion protein is successively through affinity chromatography, anion-exchange chromatography and molecular sieve
Chromatographic purifying.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
The acquisition methods of the genome 1 are:
A. design of primers
The primer sequence of recombinant chIL-2 (IL-2) is:
Upstream IL-2-F1:CCGGAATTCATGATGTGCAAAGTACT, with EcoRI restriction enzyme sites;
Downstream IL-2-R1:
ACCACCACCAGAACCACCACCACCTTTTTGCAGATATCTCAC, with flexible linker;
The primer sequence of chicken interferon gamma (IFN-γ) is:
Upstream IFN-γ-F1:
GGTGGTTCTGGTGGTGGTGGTTCTATGACTTGCCAGACTT, with flexible linker;
Downstream IFN-γ-R1:
ACCACCACCAGAACCACCACCACCGCAATTGCATCTCCTC, with flexible linker;
Chicken interferon α (IFN-α) primer sequence is:
Upstream IFN-α-F1:
GGTGGTTCTGGTGGTGGTGGTTCTCCCACCATGGCTGT, with flexible linker;
Downstream IFN-α-R1:CCCTCGAGAGTGCGCGTGTTG, with XhoI restriction enzyme sites;
B. RNA is extracted from chicken liver, the target gene of chicken IL-2 gene, chicken IFN-γ and chicken IFN-α is obtained by reverse transcription,
The gene order of three respectively as shown in the > of 400 < of SEQUENCE LISTING 4, the > of 400 < of SEQUENCE LISTING 5 and
Shown in the > of 400 < of SEQUENCE LISTING 6;
Respectively using the target gene of chicken IL-2 gene, chicken IFN-γ and chicken IFN-α as template, and it is utilized respectively chicken IL-2 gene, chicken
The upstream and downstream primer of IFN-γ and chicken IFN-α enters performing PCR amplification, respectively obtains the chicken IL-2 gene for connecting flexible linker, chicken
IFN-γ and chicken IFN-α gene.
PCR reaction systems and condition are:In 25 μ L overall reaction system, the μ L of template ribonucleic acid 1.5, upstream and downstream primer is each
0.5 μ L, reverse transcriptase 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;The reaction of the RT-PCR reactions
Condition is:50 DEG C of reverse transcriptions 30min, 95 DEG C of pre-degeneration 4min, into circulation;95 DEG C of denaturation 45s, 58 DEG C of annealing 45s, 72 DEG C are prolonged
1kb/min is stretched, is circulated 35 times, last 72 DEG C of extensions 10min.
C. rIL2-IFN γ genes are obtained using flexible linker connection chicken IL-2 genes and chicken IFN-γ target gene
The PCR reaction systems and reaction condition of connection be:In 25 μ L overall reaction system, connect flexible linker's
The μ L of IL-2 gene templates DNA 1, the flexible linker μ L of 1 μ L, IL-2 sense primer of IFN-γ template DNA 0.5 are connected,
0.5 μ L, Taq archaeal dna polymerase of IFN-γ anti-sense primer 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Even
Connecing PCR reaction conditions is:95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extension 1kb/
Min, totally 35 circulations;Last 72 DEG C of extensions 10min.
D. rIL2-IFN γ-IFN are obtained using flexible linker connections rIL2-IFN γ genes and chicken IFN-α target gene
α genes
The PCR reaction systems and reaction condition of connection be:In 25 μ L overall reaction system, rIL2-IFN γ gene templates
The μ L of DNA 1, connect the flexible linker μ L of 1 μ L, IL-2 sense primer of IFN-α template DNA 0.5, IFN-α anti-sense primer 0.5
μ L, Taq archaeal dna polymerase 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Connecting PCR reaction conditions is:
95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, totally 35 circulate;Most
72 DEG C of extension 10min afterwards.
Genome 2 is artificial synthesized gene after being optimized to genome 1, the acquisition methods of the genome 2
For:
A. design of primers
The primer sequence of recombinant chIL-2 (IL-2) is:
Upstream IL-2-F2:CGGGATCCATGATGTGCAAAGTTCT, with BamHI restriction enzyme sites;
Downstream IL-2-R2:
ACCACCACCAGAACCACCACCACCTTTCTGCAGGTAACG, with flexible linker;
The primer sequence of chicken interferon gamma (IFN-γ) is:
Upstream IFN-γ-F2:
GGTGGTTCTGGTGGTGGTGGTTCTATGACCTGCCAGAC, with flexible linker;
Downstream IFN-γ-R2:
ACCACCACCAGAACCACCACCACCGCAGTTGCAACGAC, with flexible linker;
Chicken interferon α (IFN-α):
Upstream IFN-α-F2:
GGTGGTTCTGGTGGTGGTGGTTCTCCGACCATGGCTG, with flexible linker;
Downstream IFN-α-R2:
CCCTCGAGGGTACGGGTGTTACC, with XhoI restriction enzyme sites.
B. the target gene of the chicken IL-2 gene, chicken IFN-γ and chicken IFN-α, the gene order of three is respectively such as SEQUENCE
Shown in the > of 400 < of LISTING 7, the > of 400 < of SEQUENCE LISTING 400 <, 8 > and SEQUENCE LISTING 9;
Respectively using the target gene of chicken IL-2 gene, chicken IFN-γ and chicken IFN-α as template, and it is utilized respectively chicken IL-2 gene, chicken
The upstream and downstream primer of IFN-γ and chicken IFN-α enters performing PCR amplification, respectively obtains the chicken IL-2 gene for connecting flexible linker, chicken
IFN-γ and chicken IFN-α gene.
PCR reaction systems and condition are:In 25 μ L overall reaction system, the μ L of genomic DNA 1.0, upstream and downstream primer is each
0.5 μ L, Taq archaeal dna polymerase 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;The RT-PCR reactions
Reaction condition is:95 DEG C of pre-degeneration 4min, into circulation;95 DEG C of denaturation 45s, 60 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, are followed
Ring 35 times, last 72 DEG C of extensions 10min.
C. rIL2-IFN γ genes are obtained using flexible linker connection chicken IL-2 genes and chicken IFN-γ target gene
The PCR reaction systems and reaction condition of connection be:In 25 μ L overall reaction system, connect flexible linker's
The μ L of IL-2 gene templates DNA 1, the flexible linker μ L of 1 μ L, IL-2 sense primer of IFN-γ template DNA 0.5 are connected,
0.5 μ L, Taq archaeal dna polymerase of IFN-γ anti-sense primer 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Even
Connecing PCR reaction conditions is:95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extension 1kb/
Min, totally 35 circulations;Last 72 DEG C of extensions 10min.
D. rIL2-IFN γ-IFN are obtained using flexible linker connections rIL2-IFN γ genes and chicken IFN-α target gene
α genes
The PCR reaction systems and reaction condition of connection be:In 25 μ L overall reaction system, rIL2-IFN γ gene templates
The μ L of DNA 1, connect the flexible linker μ L of 1 μ L, IL-2 sense primer of IFN-α template DNA 0.5, IFN-α anti-sense primer 0.5
μ L, Taq archaeal dna polymerase 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Connecting PCR reaction conditions is:
95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, totally 35 circulate;Most
72 DEG C of extension 10min afterwards.
Present invention also offers the application of the recombination chicken long-acting interferon, its long half time had up to more than 73 hours
Broad-spectrum disease resistance toxic action and the immune response that chicken itself can be improved.
Compared with prior art, the present invention has the advantages that:
1. chicken IL-2 gene, chicken IFN-γ and chicken IFN-α gene are realized into amalgamation and expression by flexible linker, interference is improved
Plain half-life period, compared with plain interferon, improve more than 18 times;
2. by being optimized to chicken IL-2 gene, chicken IFN-γ and chicken IFN-α gene, improve chicken IL-2 gene, chicken IFN-γ and
The expression quantity of chicken IFN-α fusion protein.
3. using recombination bacillus coli pET-32a/rIL2-IFN γ-IFN α as expression bacterial strain, by introducing molecular chaperones
PGro7 plasmids, in protein expression, generation inclusion body is less, forms great amount of soluble albumen, avoids inclusion body denaturation and answers
The process of property, substantially reduce the time of expressing fusion protein;
4. the fusion protein disclosed by the invention being made up of chicken IL-2 gene, chicken IFN-γ and chicken IFN-α not only has IFN-α
Broad-spectrum disease resistance toxic action, while significantly improve the immune response of chicken itself.
Brief description of the drawings
Fig. 1 is recombinant chIL-2 gene, chicken interferon α genes and the chicken interferon gamma gene RT-PCR in embodiment 1
The result of amplification;Swimming lane M:DNA Marker DL2000;Swimming lane 1:The gene RT-PCR amplified productions of chicken interleukin-2 2;Swimming lane 2:Chicken
Interferon-gamma gene RT-PCR amplified productions;Swimming lane 3:Chicken interferon α gene RT-PCR amplified productions;
Fig. 2 is the knot of the PCR amplifications after chicken IL-2 gene, the IFN-γ in embodiment 1 connect with the target gene of IFN-α
Fruit;Swimming lane M:DNA Marker DL2000;Swimming lane 1:The gene of chicken interleukin-2 2, chicken interferon gamma gene and chicken interferon α genes
Ligation amplification product;
Fig. 3 is PCR amplifications and the double digestion qualification result of the positive colony plasmid in embodiment 1;Swimming lane M:DNA
Marker DL10000;Swimming lane 1:Recombinant plasmid double digestion result;Swimming lane 2:Plasmid PCR result;
Fig. 4 is the SDS-PAGE electrophoretic examinations results of the recombinant protein in embodiment 1;Swimming lane M:Albumen Marker;Swimming lane
1:Zero load control;Swimming lane 2:Precipitated after bacterial cell disruption after recombinant bacterium induction;Swimming lane 3:After bacterial cell disruption after recombinant bacterium induction
Supernatant;
Fig. 5 is the Western Blot qualification results for the fusion protein that embodiment 1 obtains;Swimming lane M:Albumen Marker;Swimming
Road 1:Supernatant after recombinant bacterium induction is broken;Swimming lane 2:Precipitated after being crushed for recombinant bacterium induction;
Fig. 6 is that the recombination chicken long-acting interferon α as made from the fusion protein in embodiment 1 causes cell to VSV in embodiment 5
The inhibitory action of lesion;1 is VSV virus control wells;2 be HEp-2 cell control wells;A3-12 is gradient dilution (from right to left)
Human interferon standard items processing hole;B3-12 is that the recombination chicken long-acting interferon α of gradient dilution (from right to left) handles hole;
Fig. 7 is the recombination chicken long-acting interferon α intramuscular injection blood as made from the fusion protein in embodiment 1 in embodiment 8
Concentration-time changing curve.
Embodiment
Embodiment 1
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, its preparation method are as follows:
1. recombinant chIL-2 (IL-2), chicken interferon gamma (IFN-γ) and chicken interferon α (IFN-α) target gene
Obtain and expand
Design of primers:
Objective gene sequence design synthetic primer according to having been reported in Genebank is shown in Table 1, in recombinant chIL-2
EcoRI restriction enzyme sites and Linker sequences are introduced in sense primer and anti-sense primer respectively, in the sense primer of chicken interferon gamma
With Linker sequences are introduced in anti-sense primer respectively, introduced respectively in chicken interferon α sense primer and anti-sense primer
Linker sequences and XhoI restriction enzyme sites.
The pcr amplification primer thing of table 1
RT-PCR obtains target gene:
RNA is extracted from chicken liver tissue, the purpose base of chicken IL-2 gene, chicken IFN-γ and chicken IFN-α is obtained by reverse transcription
Cause, the gene order of three respectively such as the > of 400 < of SEQUENCE LISTING 4, the > of 400 < of SEQUENCE LISTING 5 and
Shown in the > of 400 < of SEQUENCE LISTING 6;
RT-PCR reaction systems (25 μ L) are shown in Table 2
The RT-PCR reaction systems of table 2
| RNase Free water | 10μL |
| dNTP Mix | 10μL |
| Reverse transcriptase | 2.5μL |
| Upstream and downstream primer | Each 0.5 μ L |
| Geneome RNA | 1.5μL |
Response parameter is:50 DEG C of reverse transcriptions 30min, 95 DEG C of pre-degeneration 4min, into circulation:95 DEG C of denaturation 45s;58 DEG C are moved back
Fiery 45s, 72 DEG C of extension 1kb/min, totally 35 circulations;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 460bp, 550bp and 610bp or so in RT-PCR amplified productions, its
As a result as shown in figure 1, the chicken IL-2 gene for being connected to flexible linker sequences, chicken IFN-γ and chicken has been prepared in explanation respectively
The target gene of IFN-α.
2. the connection of target gene
Target gene is diluted to 10ug/mL, connects each section of target gene using over-lap PCR, 25 μ L reaction systems are such as
Shown in table 3, table 4:
The rIL2-IFN γ PCR reaction systems of table 3
The rIL2-IFN γ of table 4-IFN α PCR reaction systems
Response parameter is:95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 circulations;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 1570bp or so in pcr amplification product, its result as shown in Fig. 2
Occur rIL2-IFN γ and IFN-α amplified production band in Fig. 2, because being connected in rIL2-IFN γ with IFN-α gene
During, there is non-specific responding.The nucleotide sequence of the obtained target gene such as > of 400 < of SEQUENCE LISTING 2
It is shown.
3. expression vector establishment
After sequencing is errorless, PCR glue reclaims product uses target gene after selection connection with pET-32a plasmids
EcoRI and XhoI restriction enzymes carry out double digestion and recovery, and double digestion is done by 20 μ L systems in table 5:
The double digestion system of table 5
The digestion recovery product of target gene after connection and pET-32a plasmids is attached by the system in table 6,4
DEG C overnight connection:
The enzyme disjunctor system of table 6
| Purpose fragment DNA | 10μL |
| Expression vector | 3μL |
| buffer | 2μL |
| Ligase | 1μL |
| RNase Free water | 4μL |
Connection product is converted into e. coli bl21 (DE3) competent cell, competent cell is coated on benzyl containing ammonia
The LB culture medium flat plates of penicillin are incubated overnight;Single bacterium colony on picking LB flat boards carries out target gene PCR identifications, positive colony
Bacteria plasmid is identified through EcoRI and XhoI double digestions, is accredited as positive and is represented that engineering bacteria successfully constructs, PCR amplifications and double digestion
Product detects single band through agarose gel electrophoresis at 1570bp or so places, and its result is as shown in figure 3, illustrate successfully to obtain
PET-32a/rIL2-IFN γ-IFN α engineering bacteria.
4. the expression of recombinant protein
Picking engineering bacteria 37 DEG C of shaking table recovery 1h in the LB culture mediums containing 100 μ g/ml ampicillins, in LB culture mediums
Amplification culture 4h (OD=1.0) in (the μ g/ml containing ampicillin 100), adds final concentration of 100 μ g/ml IPTG, 32 DEG C lure
Lead expression 5h;Thalline is collected, through SDS-PAGE electrophoresis detections, its result is as shown in figure 4, it can be seen that recombinant bacterium lures
Supernatant is deposited in the visible predominant expression band in 75.7KD or so places after leading the bacterial cell disruption after 5h, illustrates in precipitation and supernatant
Equal successful expression fusion protein.
Add mass volume ratio 1:Precipitation is resuspended in 1 PBS;- 20 DEG C precipitate 3 times in room temperature multigelation;4 DEG C of ultrasonic degradations
Bacterial precipitation, work 10s, is spaced 3S, ultrasonic 6min, and whole process repeats 3~4 times;4 DEG C, 12000r/min centrifugation 15min,
Supernatant, precipitation are taken respectively, obtain rough fusion protein.
5. fusion protein purification
5.1His affinity chromatography
After membrane filtration of the rough fusion protein with 0.22 μm of aperture, loading is by being connected to AKTA explorer 100
On protein purification system, the His affinity columns that have been balanced with Binding Buffer I (PBS) are washed away not with PBS
With reference to albumen, until A280nm is stable, then with Elution buffer I (50mM trishydroxymethylaminomethanes, 20~500mM
Imidazoles, PH8.0) elution, collect rIL2-IFN γ-IFN α protein peak.
5.2DEAE anion-exchange chromatography
(the 50mM trihydroxy methyls of Binding Buffer II are arrived into the albumen collected after His affinitive layer purifications displacement
Aminomethane, PH6.5) in after, DEAE anion exchange chromatography that loading has balanced by using Binding Buffer II, then
After crossing post to A280nm value stabilizations with Binding Buffer II, with (the 50mM trihydroxy methyl amino first of Elution Buffer II
Alkane, 1M NaCl, PH6.5) linear gradient elution, collect rIL2-IFN γ-IFN α protein peak.
5.3 sieve chromatography
Loading is by using (the 50mM of Binding Buffer III after the sample concentration that ion-exchange chromatography is collected into
Na2HPO4,0.15M NaCl, PH7.4) molecular sieve chromatographies of Superdex 200 have been balanced, washed with Binding Buffer III
It is de-, collect rIL2-IFN γ-IFN α protein peak.
5.4 sample identification
Determine rIL2-IFN γ-IFN α potency and specific activity, specific activity >=107IU/mg, albumen are qualified;It is aseptic subpackaged ,-
80 DEG C of preservations.The i.e. available fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, its amino acid
Sequence is as shown in the > of 400 < of SEQUENCE LISTING 1.
Embodiment 2
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, other same embodiments
1, simply e. coli bl21 therein (DE3) competent cell is replaced in order to which the BL21 (DE3) with pGro7 plasmids experiences
State cell.The SDS-PAGE electrophoresis results of its fusion protein compare with embodiment 1,75.7KD or so places predominant expression in supernatant
Band is thicker, illustrates after introducing molecular chaperones pGro7, expression of the destination protein in supernatant is more preferable, obtained fusion protein
Amount is higher.The albumen of Bacillus coli expression is mostly present in inclusion body;By introducing molecular chaperones in bacterial strain is expressed, association
Correctly folded with expressing protein, reach solubility expression of protein.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
Embodiment 3
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, its preparation method is such as
Under:
1. recombinant chIL-2 (IL-2), chicken interferon gamma (IFN-γ) and chicken interferon α (IFN-α) target gene
Obtain and expand
Chicken IL-2 gene in embodiment 1, chicken IFN-γ and chicken IFN-α are optimized, artificial synthesized chicken IL-2 gene, chicken IFN-γ
With chicken IFN-α target gene, after optimization, the nucleotide sequence of three respectively as the > of 400 < of SEQUENCE LISTING 7,
Shown in the > of 400 < of SEQUENCE LISTING 400 <, 8 > and SEQUENCE LISTING 9.
1.1 codon optimization
Genetic codon has 64 kinds, but most biological tendencies are in utilizing the part in these codons.Those
By the most frequent referred to as optimal codon (optimal codons) utilized, what those were not frequently utilized that is referred to as rare or utilizes
The low codon of rate (rare or low-usage codons).In fact, conventional do protein expression or every kind of biology of production
(including Escherichia coli, yeast, mammalian cell, plant cell and insect cell) all shows codon profit to a certain degree
Difference or preference.In Escherichia coli, yeast and drosophila to the expression efficiency of the gene containing optimal codon apparently higher than containing
The expression efficiency of the gene of the codon of poor efficiency.Therefore, in heterologous expression system, the preferences of codon are largely
On have impact on the expression of recombinant protein.Using preference codon (preferred codons) and avoid utilizing rare codon
Gene chemical synthesis is carried out, the redesign of this gene is codon optimization.Therefore, the IL-2 in the present embodiment to chicken, chicken IFN-
γ and chicken IFN-α gene codon optimize.
Interpretation of result after 1.2 codon optimizations
It is optimal efficient in the expression system to be considered as the gene during usual codon adaptation indexI (CAI)=1.0
Expression status, CAI values are lower to show that expression is lower in host.In gene G/C content most ideal distribution scope be 30~
70%, it can influence translation and transcriptional efficiency more than the scope in any region.Chicken IL-2 gene, chicken are found using software detection
The codon of IFN-γ and chicken IFN-α original gene codon adaptation indexI (CAI) in Escherichia coli is respectively 0.27,
0.25th, 0.31, GC percentages are 36.1%, 42.9%, 61.7%;And by chicken IL-2 gene, chicken IFN-γ and chicken IFN-α gene
Obtained after optimization recombination codon adaptation indexI (CAI) in Escherichia coli be respectively 1.0,1.0,1.0, GC percentages
46.2%th, 47.6%, 58.5%.The utilization rate of low codon is significantly reduced by gene optimization, avoids rare codon
Influence to protein expression, the G/C content of gene is improved, improve transcription and translation efficiency.
1.3 design of primers:
The pcr amplification primer thing of table 7
The genomic DNA of chicken IL-2 gene after optimization, chicken IFN-γ and chicken IFN-α is diluted to 0.05mg/mL respectively.Utilize
PCR amplifications obtain target gene, and 25 μ L reaction systems are as shown in table 8:
The PCR reaction systems of table 8
| RNase Free water | 10.5μL |
| dNTP Mix | 10.0μL |
| Taq archaeal dna polymerases | 2.5μL |
| Upstream and downstream primer | Each 0.5 μ L |
| Genomic DNA | 1.0μL |
Response parameter is:95 DEG C of pre-degeneration 4min, into circulation:95 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 circulations;Last 72 DEG C of extensions 10min.
Chicken IL-2 gene, chicken IFN-γ and chicken IFN-α pcr amplification product through agarose gel electrophoresis respectively 610bp,
There is specific band in 550bp and 460bp or so, illustrate the chicken for being connected to flexible linker after optimization has been prepared
IL-2, chicken IFN-γ and chicken IFN-α target gene.
2. the connection of target gene
Target gene is diluted to 10ug/mL, connects each section of target gene using over-lap PCR, 25 μ L reaction systems are such as
Shown in table 9, table 10:
The rIL2-IFN γ PCR reaction systems of table 9
The rIL2-IFN γ of table 10-IFN-α PCR reaction systems
Response parameter is:95 DEG C of pre-degeneration 4min, into circulation:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 circulations;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 1570bp or so in pcr amplification product, illustrates successfully to be connected
RIL2-IFN γ-IFN-α gene after connecing.The nucleotide sequence of obtained target gene such as SEQUENCE LISTING 400
Shown in the > of < 3.
3. expression vector establishment
The PCR errorless after sequencing of the target gene after connection glue reclaim product is selected to be used with pET-32a plasmids
BamHI, XhoI restriction enzyme carry out double digestion and recovery, and double digestion is done by 20 μ L systems in table 11:
The double digestion system of table 11
| General buffer | 2μL |
| Restriction enzyme (a pair) | 1μL+1μL |
| Carrier or recovery fragment | 2ul |
| RNase Free water | 14μL |
The digestion recovery product of target gene after connection and pET-32a plasmids is attached by the system in table 12,4
DEG C overnight connection:
Table 12
| Purpose fragment DNA | 10μL |
| Expression vector | 3μL |
| buffer | 2μL |
| Ligase | 1μL |
| RNase Free water | 4μL |
Connection product is converted into e. coli bl21 (DE3) competent cell, competence is coated on the mould of benzyl containing ammonia
It is incubated overnight in the LB flat boards of element;The bacterium colony grown on LB flat boards is taken to identify target gene, positive colony bacteria plasmid warp through PCR
BamHI, XhoI double digestion are identified, are accredited as positive and are represented expression vector establishment success, PCR amplifications and double digestion product are through fine jade
There is single band at 1570bp or so places in sepharose electrophoresis, illustrates containing rIL2-IFN γ-IFN α fusion gene engineering bacterium
PET-32a/rIL2-IFN γ-IFN α successfully constructs.
4. the expression of recombinant protein
Picking engineering bacteria 37 DEG C of shaking table recovery 1h in the LB culture mediums containing 100 μ g/ml ampicillins, in LB culture mediums
Amplification culture 4h (OD=1.0) in (the μ g/ml containing ampicillin 100), adds final concentration of 100 μ g/ml IPTG, 32 DEG C lure
Lead expression 5h;Thalline is collected, through SDS-PAGE electrophoresis detections, supernatant is deposited in after the bacterial cell disruption after recombinant bacterium induction 5h
The visible predominant expression band in 75.7KD or so places, illustrate to have obtained recombinant protein in supernatant precipitates.
Add mass volume ratio 1:Precipitation is resuspended in 1 PBS;- 20 DEG C precipitate 3 times in room temperature multigelation;4 DEG C of ultrasonic degradations
Bacterial precipitation, work 10s, is spaced 3S, ultrasonic 6min, and whole process repeats 3~4 times;4 DEG C, 12000r/min centrifugation 15min,
Supernatant, precipitation are taken respectively, obtain rough fusion protein.
5. fusion protein purification
5.1His affinity chromatography
After membrane filtration of the rough fusion protein with 0.22 μm of aperture, loading is by being connected to AKTA explorer 100
On protein purification system, the His affinity columns that have been balanced with Binding Buffer I (PBS) are washed away not with PBS
With reference to albumen, until A280nm is stable, then with Elution buffer I (50mM trishydroxymethylaminomethanes, 20~500mM
Imidazoles, PH8.0) elution, collect rIL2-IFN γ-IFN α protein peak.
5.2DEAE anion-exchange chromatography
(the 50mM trihydroxy methyls of Binding Buffer II are arrived into the albumen collected after His affinitive layer purifications displacement
Aminomethane, PH6.5) in after, DEAE anion exchange chromatography that loading has balanced by using Binding Buffer II, then
After crossing post to A280nm value stabilizations with Binding Buffer II, with (the 50mM trihydroxy methyl amino first of Elution Buffer II
Alkane, 1M NaCl, PH6.5) linear gradient elution, collect rIL2-IFN γ-IFN α protein peak.
5.3 sieve chromatography
Loading is by using Binding Buffer III after the sample concentration that ion-exchange chromatography is collected into
(50mMNa2HPO4,0.15M NaCl, PH7.4) molecular sieve chromatographies of Superdex 200 have been balanced, with Binding Buffer
III elution, collects rIL2-IFN γ-IFN α protein peak.
5.4 sample identification
Determine rIL2-IFN γ-IFN α potency and specific activity, specific activity >=107IU/mg, albumen are qualified;Sterile point
Dress, -80 DEG C of preservations.The i.e. available fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, its ammonia
Base acid sequence is as shown in the > of 400 < of SEQUENCE LISTING 1.
Embodiment 4
A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, other same embodiments
3, simply e. coli bl21 therein (DE3) competent cell is replaced in order to which the BL21 (DE3) with pGro7 plasmids experiences
State cell.The SDS-PAGE electrophoresis results of its fusion protein compare with embodiment 3,75.7KD or so places predominant expression in supernatant
Band is thicker, illustrates after introducing molecular chaperones pGro7, expression of the destination protein in supernatant is more preferable, obtained fusion protein
Amount is higher.The albumen of Bacillus coli expression is mostly present in inclusion body;By introducing molecular chaperones in bacterial strain is expressed, association
Correctly folded with expressing protein, reach solubility expression of protein.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
Embodiment 5
A kind of recombination chicken long-acting interferon α, by the fusion protein in embodiment 1,2,3,4 respectively with freeze drying protectant mixture
Afterwards, it is freeze-dried to form.The freeze drying protectant is glycerine, mannitol and sucrose, is buffer solution with 10mmol/L PBS,
Final concentration of glycerine 100mL/L, mannitol 0.12g/mL and the sucrose 0.025g/mL of three.
Embodiment 6
Embodiment 1~4 is obtained by the mirror of recombinant chIL-2, chicken interferon gamma and chicken interferon the α fusion protein formed
It is fixed
The quantitative detection of 6.1 protein contents
With Lowry methods, the standard protein that institute is examined and determine with Chinese food pharmaceutical biological product is made standard test, determines embodiment
1~4 obtained fusion protein concentration is all higher than 1.1mg/ml.
6.2SDS-PAGE electrophoresis detection
Compared with empty bacterium, fusion protein has the newly-increased protein band of a dense dye in 75.7KD or so, as shown in Figure 4.
6.3Western Blot results
Fusion protein in embodiment 1~4 is detected respectively, with the anti-chicken alpha interferon (1 of abcam companies mouse:5000 dilutions) it is one
It is anti-, using goat anti-mouse IgG-HRP as secondary antibody (1:10000 dilutions).Recombination chicken long-acting interferon sample can be with anti-chicken interferon α
Monoclonal antibody occurs specific reaction, 75.7KD or so place and specific band occurs, as shown in Figure 5.
Embodiment 7
Bioactivity freeze-dried four parts of recombination chicken long-acting interferon α in embodiment 5
Suppress method according to few cells lesion, Hep-2 cells are made into 5 × 10 with culture medium5Cell/ml cells suspend
Liquid, per hole, inoculation 0.1ml moves into 96 porocyte culture plates.37 DEG C, 5%CO224h is cultivated, adds the recombination chicken length of various dose
Interferon-' alpha ' is imitated, inhales and abandons after 24h, then be inoculated with 100TCID respectively50VSV viruses.
Result of the test
As a result the recombination chicken long-acting interferon α for showing to obtain causes the lesion of HEp-2 cells to have obvious suppress to VSV
Effect.The lesion such as occurs cell rounding after undressed cell virus inoculation, comes off, is disintegrated.And the recombination chicken length obtained
After imitating the cell virus inoculation after interferon-' alpha ' processing, the Continuous Observation under inverted microscope, cellular morphology is normal, does not go out incumbent
What lesion, measures potency >=107IU/ml, as shown in Figure 6.
Embodiment 8
The four parts of recombination chicken long-acting interferon α obtained respectively by the fusion protein of embodiment 1~4 in embodiment 5 are freezed
The measure of half-life period of the agent (being designated as A, B, C, D respectively) in chicken body
The blood concentration and time relationship of cytopathic-effect inhibition assay measure rIL2-IFN γ-IFN α
The broiler chicken (male and female half and half) that six body weight are roughly the same is taken, 2mg/ml recombination chicken long-acting interferons are subcutaneously injected in neck
The freeze-dried 2ml of α, respectively in 1h, 2h, 4h, 8h, 16h, 32h, 64h, 96h venous blood collection, 4 DEG C of solidifications of blood sample, 3500rpm low temperature
10min separation serum is centrifuged, each every chicken blood sample of time point is to be measured in -20 DEG C of preservations.Serum is determined using cytopathic-effect inhibition assay
The concentration of rIL2-IFN γ-IFN α in sample, carried out curve fitting and calculating parameter with DAS pharmacokinetics softwares.Parameter calculates knot
Fruit is shown in Table 13.
Dominant dynamic parameters in serum after the recombination chicken long-acting interferon α intramuscular injection of table 13
As a result show that recombination chicken long-acting interferon α has longer half-life period.Half-life period can reach 73h or so after measured, compared with
Plain interferon improves more than 18 times.
Embodiment 9
The freeze-dried measure influenceed on chicken cell immune response of four parts of recombination chicken long-acting interferon α in embodiment 5
Take six roughly the same broiler chicken of body weight to be divided into two groups, be designated as experimental group and control group;Experimental group neck is subcutaneously noted
The 2mg/ml recombination chicken long-acting interferon freeze-dried 2ml of α are penetrated, 2mL PBS is subcutaneously injected in control group neck, takes after injecting 4 weeks outside chicken
All blood, take a blood weekly afterwards, separate lymphocyte using lymphocyte separation medium, lymphocyte passes through serum-free RPMI
After 1640 culture mediums wash 2 times, it is resuspended with complete medium, adjusts cell concentration as 2 × 106Individual/ml, 24 porocyte culture plates are every
Hole addition 1ml lymphocytes, 37 DEG C, 5%CO272h is cultivated, supernatant when collecting lymphocyte culture.ELISA detects culture supernatant
Middle IL-4 contents, are carried out, testing result is as shown in table 14 by kit specification:
The ELISA of table 14 detection each group chicken cell immune responses are horizontal
As a result show after injecting recombination chicken long-acting interferon α, can significantly improve chicken Evaluation of Cytokines in Peripheral Blood IL-4's
Content, cellullar immunologic response level is enhanced, significantly improves immunity level.
It is above-mentioned with reference to embodiment to a kind of fusion egg being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α
The detailed description that bletilla its preparation method is carried out, is illustrative rather than limited, can be included according to limited scope
Several embodiments, therefore changing and modifications in the case where not departing from present general inventive concept, should belong to protection scope of the present invention it
It is interior.
SEQUENCE LISTING
<110>Anhui Jiuchuan Biotechnology Co., Ltd.
<120>A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and its preparation
Method
<130> 1
<160> 9
<170> PatentIn version 3.3
<210> 1
<211> 522
<212> PRT
<213>Chicken IL2-IFN γ-IFN α fusion protein
<400> 1
Met Met Cys Lys Val Leu Ile Phe Gly Cys Ile Ser Val Ala Met Leu
1 5 10 15
Met Thr Thr Ala Tyr Gly Ala Ser Leu Ser Ser Glu Lys Trp Lys Thr
20 25 30
Leu Gln Thr Leu Ile Lys Asp Leu Glu Ile Leu Glu Asn Ile Lys Asn
35 40 45
Lys Ile His Leu Glu Leu Tyr Thr Pro Thr Glu Thr Gln Glu Cys Thr
50 55 60
Gln Gln Thr Leu Gln Cys Tyr Leu Gly Glu Val Val Thr Leu Lys Lys
65 70 75 80
Glu Thr Glu Asp Asp Thr Glu Ile Lys Glu Glu Phe Val Thr Ala Ile
85 90 95
Gln Asn Ile Glu Lys Asn Leu Lys Ser Leu Thr Gly Leu Asn His Thr
100 105 110
Gly Ser Glu Cys Lys Ile Cys Glu Ala Asn Asn Lys Lys Lys Phe Pro
115 120 125
Asp Phe Leu His Glu Leu Thr Asn Phe Val Arg Tyr Leu Gln Lys Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Thr Cys Gln Thr Tyr Asn
145 150 155 160
Leu Phe Val Leu Ser Val Ile Met Ile Tyr Tyr Gly His Thr Ala Ser
165 170 175
Ser Leu Ile Leu Val Gln Leu Gln Asp Asp Ile Ala Lys Leu Lys Ala
180 185 190
Asp Phe Asn Ser Ser His Ser Asp Val Ala Asp Gly Gly Pro Ile Ile
195 200 205
Ala Glu Lys Leu Lys Asn Trp Thr Glu Arg Asn Gln Lys Arg Ile Ile
210 215 220
Leu Ser Gln Ile Val Ser Met Tyr Leu Glu Met Leu Ala Asn Thr Asp
225 230 235 240
Lys Thr Lys Pro His Thr Lys His Ile Ser Glu Glu Leu Tyr Thr Leu
245 250 255
Lys Asn Asn Leu Pro Asp Gly Val Lys Lys Val Lys Asp Ile Met Asp
260 265 270
Leu Ala Lys Leu Pro Met Asn Asp Leu Arg Val Gln Leu Lys Ala Ala
275 280 285
Asn Glu Leu Phe Ser Ile Leu Gln Lys Leu Val Asn Pro Pro Ser Phe
290 295 300
Lys Arg Asn Met Ser Gln Ser Gln Arg Arg Cys Asn Cys Gly Gly Gly
305 310 315 320
Gly Ser Gly Gly Gly Gly Ser Pro Thr Met Ala Val Pro Ala Ser Pro
325 330 335
Gln His Pro Arg Gly Tyr Gly Ile Leu Leu Leu Thr Leu Leu Leu Lys
340 345 350
Ala Leu Ala Thr Thr Ala Ser Ala Cys Asn His Leu Arg Pro Gln Asp
355 360 365
Ala Thr Phe Ser His Asp Ser Leu Gln Leu Leu Arg Asp Met Ala Pro
370 375 380
Thr Leu Pro Gln Leu Cys Pro Gln His Asn Ala Ser Cys Ser Phe Asn
385 390 395 400
Asp Thr Ile Leu Asp Thr Ser Asn Thr Arg Gln Ala Asp Lys Thr Thr
405 410 415
His Asp Ile Leu Gln His Leu Phe Lys Ile Leu Ser Ser Pro Ser Thr
420 425 430
Pro Ala His Trp Asn Asp Ser Gln Arg Gln Ser Leu Leu Asn Arg Ile
435 440 445
His Arg Tyr Thr Gln His Leu Glu Gln Cys Leu Asp Ser Ser Asp Thr
450 455 460
Arg Ser Arg Thr Arg Trp Pro Arg Asn Leu His Leu Thr Ile Lys Lys
465 470 475 480
His Phe Ser Cys Leu His Thr Phe Leu Gln Asp Asn Asp Tyr Ser Ala
485 490 495
Cys Ala Trp Glu His Val Arg Leu Gln Ala Arg Ala Trp Phe Leu His
500 505 510
Ile His Asn Leu Thr Gly Asn Thr Arg Thr
515 520
<210> 2
<211> 1566
<212> DNA
<213>Genome 1
<400> 2
atgatgtgca aagtactgat ctttggctgt atttcggtag caatgctaat gactacagct 60
tatggagcat ctctatcatc agaaaaatgg aaaactcttc aaacattaat aaaggattta 120
gaaatattgg aaaatatcaa gaataagatt catctcgagc tctacacacc aactgagacc 180
caggagtgca cccagcaaac tctgcagtgt tacctgggag aagtggttac tctgaagaaa 240
gaaactgaag atgacactga aattaaagaa gaatttgtaa ctgctattca aaatatcgaa 300
aagaacctca agagtcttac gggtctaaat cacaccggaa gtgaatgcaa gatctgtgaa 360
gctaacaaca agaaaaaatt tcctgatttt ctccatgaac tgaccaactt tgtgagatat 420
ctgcaaaaag gtggtggtgg ttctggtggt ggtggttcta tgacttgcca gacttacaac 480
ttgtttgttc tgtccgtcat catgatttat tatggacata ctgcaagtag tctaattctt 540
gttcaacttc aagatgatat agccaaactg aaagctgact ttaactcaag tcattcagat 600
gtagctgacg gtggacctat tattgcagag aaactgaaga actggacaga gagaaatcag 660
aaaaggatca tactgagcca gattgtttcg atgtacttgg aaatgcttgc aaacactgac 720
aagacaaagc cgcacaccaa acacatatct gaggagctct atactctgaa aaacaacctt 780
cctgatggcg tgaagaaggt gaaagatatc atggacctgg ccaagctccc gatgaacgac 840
ttgagagtcc agctcaaagc cgcgaatgaa ctcttcagca tcttacagaa gctggtgaat 900
cctccgagtt tcaaaaggaa catgagccag tctcagagga gatgcaattg cggtggtggt 960
ggttctggtg gtggtggttc tcccaccatg gctgtgcctg caagcccaca gcacccacgg 1020
gggtacggca tcctgctgct cacgctcctt ctgaaagctc tcgccaccac cgcctccgcc 1080
tgcaaccacc ttcgccccca ggatgccacc ttctctcacg acagcctcca gctcctccgg 1140
gacatggctc ccacactacc ccagctgtgc ccacagcaca acgcgtcttg ctccttcaac 1200
gacaccatcc tggacaccag caacacccgg caagccgaca aaaccaccca cgacatcctt 1260
cagcacctct tcaaaatcct cagcagcccc agcactccag cccactggaa cgacagccaa 1320
cgccaaagcc tcctcaaccg gatccaccgc tacacccagc acctcgagca atgcttggac 1380
agcagcgaca cgcgctcccg gacgcgatgg cctcgcaacc ttcacctcac catcaaaaaa 1440
cacttcagct gcctccacac cttcctccaa gacaacgatt acagcgcctg cgcctgggaa 1500
cacgtccgcc tgcaagctcg tgcctggttc ctgcacatcc acaacctcac aggcaacacg 1560
cgcact 1566
<210> 3
<211> 1566
<212> DNA
<213>Genome 2
<400> 3
atgatgtgca aagtactgat ctttggctgt atttcggtag caatgctaat gactacagct 60
tatggagcat ctctatcatc agaaaaatgg aaaactcttc aaacattaat aaaggattta 120
gaaatattgg aaaatatcaa gaataagatt catctcgagc tctacacacc aactgagacc 180
caggagtgca cccagcaaac tctgcagtgt tacctgggag aagtggttac tctgaagaaa 240
gaaactgaag atgacactga aattaaagaa gaatttgtaa ctgctattca aaatatcgaa 300
aagaacctca agagtcttac gggtctaaat cacaccggaa gtgaatgcaa gatctgtgaa 360
gctaacaaca agaaaaaatt tcctgatttt ctccatgaac tgaccaactt tgtgagatat 420
ctgcaaaaag gtggtggtgg ttctggtggt ggtggttcta tgacctgcca gacctacaac 480
ctgttcgttc tgtctgttat catgatctac tacggtcaca ccgcttcttc tctgatcctg 540
gttcagctgc aggacgacat cgctaaactg aaagctgact tcaactcttc tcactctgac 600
gttgctgacg gtggtccgat catcgctgaa aaactgaaaa actggaccga acgtaaccag 660
aaacgtatca tcctgtctca gatcgtttct atgtacctgg aaatgctggc taacaccgac 720
aaaaccaaac cgcacaccaa acacatctct gaagaactgt acaccctgaa aaacaacctg 780
ccggacggtg ttaaaaaagt taaagacatc atggacctgg ctaaactgcc gatgaacgac 840
ctgcgtgttc agctgaaagc tgctaacgaa ctgttctcta tcctgcagaa actggttaac 900
ccgccgtctt tcaaacgtaa catgtctcag tctcagcgtc gttgcaactg cggtggtggt 960
ggttctggtg gtggtggttc tccgaccatg gctgttccgg cttctccgca gcacccgcgt 1020
ggttacggta tcctgctgct gaccctgctg ctgaaagctc tggctaccac cgcttctgct 1080
tgcaaccacc tgcgtccgca ggacgctacc ttctctcacg actctctgca gctgctgcgt 1140
gacatggctc cgaccctgcc gcagctgtgc ccgcagcaca acgcttcttg ctctttcaac 1200
gacaccatcc tggacacctc taacacccgt caggctgaca aaaccaccca cgacatcctg 1260
cagcacctgt tcaaaatcct gtcttctccg tctaccccgg ctcactggaa cgactctcag 1320
cgtcagtctc tgctgaaccg tatccaccgt tacacccagc acctggaaca gtgcctggac 1380
tcttctgaca cccgttctcg tacccgttgg ccgcgtaacc tgcacctgac catcaaaaaa 1440
cacttctctt gcctgcacac cttcctgcag gacaacgact actctgcttg cgcttgggaa 1500
cacgttcgtc tgcaggctcg tgcttggttc ctgcacatcc acaacctgac cggtaacacc 1560
cgtacc 1566
<210> 4
<211> 429
<212> DNA
<213>Chicken IL-2 gene
<400> 4
atgatgtgca aagtactgat ctttggctgt atttcggtag caatgctaat gactacagct 60
tatggagcat ctctatcatc agaaaaatgg aaaactcttc aaacattaat aaaggattta 120
gaaatattgg aaaatatcaa gaataagatt catctcgagc tctacacacc aactgagacc 180
caggagtgca cccagcaaac tctgcagtgt tacctgggag aagtggttac tctgaagaaa 240
gaaactgaag atgacactga aattaaagaa gaatttgtaa ctgctattca aaatatcgaa 300
aagaacctca agagtcttac gggtctaaat cacaccggaa gtgaatgcaa gatctgtgaa 360
gctaacaaca agaaaaaatt tcctgatttt ctccatgaac tgaccaactt tgtgagatat 420
ctgcaaaaa 429
<210> 5
<211> 492
<212> DNA
<213>Chicken IFN-γ
<400> 5
atgacttgcc agacttacaa cttgtttgtt ctgtccgtca tcatgattta ttatggacat 60
actgcaagta gtctaattct tgttcaactt caagatgata tagccaaact gaaagctgac 120
tttaactcaa gtcattcaga tgtagctgac ggtggaccta ttattgcaga gaaactgaag 180
aactggacag agagaaatca gaaaaggatc atactgagcc agattgtttc gatgtacttg 240
gaaatgcttg caaacactga caagacaaag ccgcacacca aacacatatc tgaggagctc 300
tatactctga aaaacaacct tcctgatggc gtgaagaagg tgaaagatat catggacctg 360
gccaagctcc cgatgaacga cttgagagtc cagctcaaag ccgcgaatga actcttcagc 420
atcttacaga agctggtgaa tcctccgagt ttcaaaagga acatgagcca gtctcagagg 480
agatgcaatt gc 492
<210> 6
<211> 585
<212> DNA
<213>Chicken IFN-α
<400> 6
cccaccatgg ctgtgcctgc aagcccacag cacccacggg ggtacggcat cctgctgctc 60
acgctccttc tgaaagctct cgccaccacc gcctccgcct gcaaccacct tcgcccccag 120
gatgccacct tctctcacga cagcctccag ctcctccggg acatggctcc cacactaccc 180
cagctgtgcc cacagcacaa cgcgtcttgc tccttcaacg acaccatcct ggacaccagc 240
aacacccggc aagccgacaa aaccacccac gacatccttc agcacctctt caaaatcctc 300
agcagcccca gcactccagc ccactggaac gacagccaac gccaaagcct cctcaaccgg 360
atccaccgct acacccagca cctcgagcaa tgcttggaca gcagcgacac gcgctcccgg 420
acgcgatggc ctcgcaacct tcacctcacc atcaaaaaac acttcagctg cctccacacc 480
ttcctccaag acaacgatta cagcgcctgc gcctgggaac acgtccgcct gcaagctcgt 540
gcctggttcc tgcacatcca caacctcaca ggcaacacgc gcact 585
<210> 7
<211> 429
<212> DNA
<213>Chicken IL-2 gene
<400> 7
atgatgtgca aagttctgat cttcggttgc atctctgttg ctatgctgat gaccaccgct 60
tacggtgctt ctctgtcttc tgaaaaatgg aaaaccctgc agaccctgat caaagacctg 120
gaaatcctgg aaaacatcaa aaacaaaatc cacctggaac tgtacacccc gaccgaaacc 180
caggaatgca cccagcagac cctgcagtgc tacctgggtg aagttgttac cctgaaaaaa 240
gaaaccgaag acgacaccga aatcaaagaa gaattcgtta ccgctatcca gaacatcgaa 300
aaaaacctga aatctctgac cggtctgaac cacaccggtt ctgaatgcaa aatctgcgaa 360
gctaacaaca aaaaaaaatt cccggacttc ctgcacgaac tgaccaactt cgttcgttac 420
ctgcagaaa 429
<210> 8
<211> 492
<212> DNA
<213>Chicken IFN-γ
<400> 8
atgacctgcc agacctacaa cctgttcgtt ctgtctgtta tcatgatcta ctacggtcac 60
accgcttctt ctctgatcct ggttcagctg caggacgaca tcgctaaact gaaagctgac 120
ttcaactctt ctcactctga cgttgctgac ggtggtccga tcatcgctga aaaactgaaa 180
aactggaccg aacgtaacca gaaacgtatc atcctgtctc agatcgtttc tatgtacctg 240
gaaatgctgg ctaacaccga caaaaccaaa ccgcacacca aacacatctc tgaagaactg 300
tacaccctga aaaacaacct gccggacggt gttaaaaaag ttaaagacat catggacctg 360
gctaaactgc cgatgaacga cctgcgtgtt cagctgaaag ctgctaacga actgttctct 420
atcctgcaga aactggttaa cccgccgtct ttcaaacgta acatgtctca gtctcagcgt 480
cgttgcaact gc 492
<210> 9
<211> 585
<212> DNA
<213>Chicken IFN-α
<400> 9
ccgaccatgg ctgttccggc ttctccgcag cacccgcgtg gttacggtat cctgctgctg 60
accctgctgc tgaaagctct ggctaccacc gcttctgctt gcaaccacct gcgtccgcag 120
gacgctacct tctctcacga ctctctgcag ctgctgcgtg acatggctcc gaccctgccg 180
cagctgtgcc cgcagcacaa cgcttcttgc tctttcaacg acaccatcct ggacacctct 240
aacacccgtc aggctgacaa aaccacccac gacatcctgc agcacctgtt caaaatcctg 300
tcttctccgt ctaccccggc tcactggaac gactctcagc gtcagtctct gctgaaccgt 360
atccaccgtt acacccagca cctggaacag tgcctggact cttctgacac ccgttctcgt 420
acccgttggc cgcgtaacct gcacctgacc atcaaaaaac acttctcttg cctgcacacc 480
ttcctgcagg acaacgacta ctctgcttgc gcttgggaac acgttcgtct gcaggctcgt 540
gcttggttcc tgcacatcca caacctgacc ggtaacaccc gtacc 585
Claims (10)
- A kind of 1. fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α, it is characterised in that:It is described The amino acid sequence table of fusion protein is as shown in the > of 400 < of SEQUENCE LISTING 1.
- A kind of 2. gene for encoding fusion protein as claimed in claim 1, it is characterised in that the nucleotide sequence of the gene Table is designated as genome 1 as shown in the > of 400 < of SEQUENCE LISTING 2;Or as shown in the > of 400 < of SEQUENCE LISTING 3, It is designated as genome 2.
- 3. the expression vector containing gene as claimed in claim 2.
- 4. the genetic engineering bacterium containing gene as claimed in claim 2.
- 5. a kind of recombination chicken long-acting interferon, it is characterised in that the recombination chicken long-acting interferon is as melting described in claim 1 It is freeze-dried to form after hop protein and freeze drying protectant mixture.
- 6. the preparation method of fusion protein according to claim 1, it is characterised in that the preparation method includes following step Suddenly:Expression vector described in claim 3 is imported into e. coli host cell, obtains genetic engineering bacterium, genetic engineering Bacterium obtains the crude product of the fusion protein after IPTG induced expressions, and fusion protein is can obtain after purified.
- 7. preparation method according to claim 6, it is characterised in that the genetic engineering bacterium is pET-32a/rIL2-IFN γ-IFN α, its preparation method are:(1) primer is designed, is obtained by reverse transcription or the sheep interleukin 2 of the flexible linker sequences of artificial synthesized band, sheep The target gene of interferon gamma, sheep interferon-tau;Recombinant chIL-2, chicken interferon gamma, chicken are disturbed by flexible linker Plain α target gene connects, the nucleotides sequence list such as > of 400 < of SEQUENCE LISTING 2 of the target gene after connection It is shown or as shown in the > of 400 < of SEQUENCE LISTING 3;(2) target gene after connection is connected on pET-32a plasmids and obtains expression vector;(3) expression vector is imported into e. coli host cell, you can obtain genetic engineering bacterium pET-32a/rIL2-IFN γ-IFNα。
- 8. the preparation method according to claim 6 or 7, it is characterised in that the e. coli host cell is BL21 (DE3) competent cell or BL21 (DE3) competent cell with pGro7 plasmids.
- 9. the preparation method according to claim 6 or 7, it is characterised in that the method for the purifying is:Fusion protein it is thick Product successively purify through affinity chromatography, anion-exchange chromatography and sieve chromatography.
- 10. the application of recombination chicken long-acting interferon according to claim 5, it is characterised in that the recombination chicken is long-acting dry The long half time of element is disturbed up to more than 73 hours, there is broad-spectrum disease resistance toxic action and the immune response of chicken itself can be improved.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710676329.3A CN107383203A (en) | 2017-08-09 | 2017-08-09 | A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof |
| CN201810768495.0A CN109053897A (en) | 2017-08-09 | 2018-07-13 | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710676329.3A CN107383203A (en) | 2017-08-09 | 2017-08-09 | A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107383203A true CN107383203A (en) | 2017-11-24 |
Family
ID=60345021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710676329.3A Pending CN107383203A (en) | 2017-08-09 | 2017-08-09 | A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof |
| CN201810768495.0A Pending CN109053897A (en) | 2017-08-09 | 2018-07-13 | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810768495.0A Pending CN109053897A (en) | 2017-08-09 | 2018-07-13 | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107383203A (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998032869A1 (en) * | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
| CN102041263B (en) * | 2010-02-08 | 2013-01-09 | 河南省动物疫病预防控制中心 | Chicken alpha interferon/interleukin 2 chimeric gene |
| CN105944096A (en) * | 2016-05-06 | 2016-09-21 | 安徽九川生物科技有限公司 | Immunoenhancer for chicken vaccine |
-
2017
- 2017-08-09 CN CN201710676329.3A patent/CN107383203A/en active Pending
-
2018
- 2018-07-13 CN CN201810768495.0A patent/CN109053897A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109053897A (en) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107353347A (en) | A kind of fusion protein being made up of pig albumin, Porcine interferon-gamma and porcine interferon alpha and preparation method thereof | |
| CN108840947A (en) | Bovine albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of ox long-acting interferon | |
| CN108840952A (en) | A kind of fusion protein and preparation method thereof being made of Chicken Albumin, chicken interferon gamma and chicken interferon α | |
| CN107253994A (en) | A kind of fusion protein being made up of pig interleukin 2 and 6, Porcine interferon-gamma and porcine interferon alpha and preparation method thereof | |
| CN108794638A (en) | A kind of recombinant bovine long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon | |
| CN107286254A (en) | Dog albumin interferon-' alpha ' interleukin-22 fusion protein, preparation method and its encoding gene, a kind of dog long-acting interferon | |
| CN107254000A (en) | A kind of fusion protein being made up of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of restructuring sheep long-acting interferon γ | |
| CN107253999A (en) | A kind of restructuring sheep long-acting interferon γ and prepare this long-acting interferon γ fusion protein and preparation method thereof | |
| CN107383205A (en) | Pig albumin interferon-' alpha ' interleukin-22 fusion protein, preparation method and its encoding gene, a boar long-acting interferon | |
| CN107253996A (en) | Sheep albumin interferon-tau interleukin-22 fusion protein, preparation method and its encoding gene, a kind of sheep long-acting interferon | |
| CN107400170A (en) | OVA interferon-' alpha ' interleukin-22 fusion protein, preparation method and its encoding gene, a breeder long-acting interferon | |
| CN108794644A (en) | A kind of fusion protein and preparation method thereof being made of cattle interleukins-2 2, Bov IFN γ and Bov IFN α | |
| CN108794645A (en) | A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α | |
| CN107383203A (en) | A kind of fusion protein being made up of recombinant chIL-2, chicken interferon gamma and chicken interferon α and preparation method thereof | |
| CN107383202A (en) | A kind of fusion protein being made up of OVA, chicken interferon gamma and recombinant chIL-2 and preparation method thereof | |
| CN107383204A (en) | A kind of fusion protein being made up of sheep interleukin 2, sheep interferon gamma and sheep interferon-tau and preparation method thereof | |
| CN107253998A (en) | A kind of fusion protein being made up of canine leucocyte interleukin 2, dog interferon γ and dog interferon alpha and preparation method thereof | |
| CN107245109A (en) | Fusion protein composed of sheep albumin, sheep interferon gamma and sheep interleukin 2 and preparation method thereof | |
| CN108864295A (en) | A kind of recombinant bovine long-acting interferon and the fusion protein for preparing this long-acting interferon and preparation method thereof | |
| CN107353348A (en) | A kind of restructuring sheep long-acting interferon τ and prepare fusion protein of this long-acting interferon and preparation method thereof | |
| CN107353349A (en) | A kind of Recombinant Swine long-acting interferon and prepare fusion protein of this long-acting interferon and preparation method thereof | |
| CN107245110A (en) | Fusion protein composed of sheep albumin, sheep interferon gamma and sheep interferon tau and preparation method thereof | |
| CN107365391A (en) | A kind of recombination chicken long-acting interferon and prepare fusion protein of this long-acting interferon and preparation method thereof | |
| CN107286256A (en) | A kind of recombination chicken long-acting interferon γ and prepare this long-acting interferon γ fusion protein and preparation method thereof | |
| CN107286252A (en) | A kind of recombination chicken long-acting interferon α and prepare fusion protein of this long-acting interferon and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171124 |
|
| WD01 | Invention patent application deemed withdrawn after publication |